These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients. Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322 [TBL] [Abstract][Full Text] [Related]
24. Serum ST2 in inflammatory bowel disease: a potential biomarker for disease activity. Boga S; Alkim H; Koksal AR; Ozagari AA; Bayram M; Tekin Neijmann S; Sen I; Alkim C J Investig Med; 2016 Jun; 64(5):1016-24. PubMed ID: 27001944 [TBL] [Abstract][Full Text] [Related]
25. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases? Kaplan M; Yuksel M; Ates I; Kilic ZM; Kilic H; Kuzu UB; Kayacetin E J Gastroenterol Hepatol; 2016 Jun; 31(6):1120-5. PubMed ID: 26642816 [TBL] [Abstract][Full Text] [Related]
26. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis. Mortensen JH; Godskesen LE; Jensen MD; Van Haaften WT; Klinge LG; Olinga P; Dijkstra G; Kjeldsen J; Karsdal MA; Bay-Jensen AC; Krag A J Crohns Colitis; 2015 Oct; 9(10):863-72. PubMed ID: 26188349 [TBL] [Abstract][Full Text] [Related]
27. Serum adipokines in inflammatory bowel disease. Waluga M; Hartleb M; Boryczka G; Kukla M; Zwirska-Korczala K World J Gastroenterol; 2014 Jun; 20(22):6912-7. PubMed ID: 24944482 [TBL] [Abstract][Full Text] [Related]
28. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Burisch J Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595 [TBL] [Abstract][Full Text] [Related]
29. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease]. Ciećko-Michalska I; Fedak D; Mach T Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350 [TBL] [Abstract][Full Text] [Related]
30. Serum Cholinesterases, a Novel Marker of Clinical Activity in Inflammatory Bowel Disease: A Retrospective Case-Control Study. Shao X; Yang L; Hu K; Shen R; Ye Q; Yuan X; Zhao Q; Shen J Mediators Inflamm; 2020; 2020():4694090. PubMed ID: 32733165 [TBL] [Abstract][Full Text] [Related]
31. ATF4 Deficiency Promotes Intestinal Inflammation in Mice by Reducing Uptake of Glutamine and Expression of Antimicrobial Peptides. Hu X; Deng J; Yu T; Chen S; Ge Y; Zhou Z; Guo Y; Ying H; Zhai Q; Chen Y; Yuan F; Niu Y; Shu W; Chen H; Ma C; Liu Z; Guo F Gastroenterology; 2019 Mar; 156(4):1098-1111. PubMed ID: 30452920 [TBL] [Abstract][Full Text] [Related]
32. Low mannose-binding lectin (MBL) is associated with paediatric inflammatory bowel diseases and ileal involvement in patients with Crohn disease. Kovacs M; Papp M; Lakatos PL; Jacobsen S; Nemes E; Polgar M; Solyom E; Bodi P; Horvath A; Molnar K; Szabo D; Cseh A; Muller KE; Dezsofi A; Arato A; Veres G J Crohns Colitis; 2013 Mar; 7(2):134-41. PubMed ID: 22504031 [TBL] [Abstract][Full Text] [Related]
33. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease. Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992 [TBL] [Abstract][Full Text] [Related]
34. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035 [TBL] [Abstract][Full Text] [Related]
35. Fecal Human Neutrophil Peptide Levels Correlate with Intestinal Inflammation in Ulcerative Colitis. Kanmura S; Hamamoto H; Morinaga Y; Oda K; Fujita T; Arima S; Nasu Y; Sasaki F; Hashimoto S; Taguchi H; Setoyama H; Ido A Digestion; 2016; 93(4):300-8. PubMed ID: 27220673 [TBL] [Abstract][Full Text] [Related]
36. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942 [TBL] [Abstract][Full Text] [Related]
37. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Solem CA; Loftus EV; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ Inflamm Bowel Dis; 2005 Aug; 11(8):707-12. PubMed ID: 16043984 [TBL] [Abstract][Full Text] [Related]
38. Association of Anti-glycan Antibodies and Inflammatory Bowel Disease Course. Paul S; Boschetti G; Rinaudo-Gaujous M; Moreau A; Del Tedesco E; Bonneau J; Presles E; Mounsef F; Clavel L; Genin C; Flourié B; Phelip JM; Nancey S; Roblin X J Crohns Colitis; 2015 Jun; 9(6):445-51. PubMed ID: 25895876 [TBL] [Abstract][Full Text] [Related]
39. Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt. Esmat S; El Nady M; Elfekki M; Elsherif Y; Naga M World J Gastroenterol; 2014 Jan; 20(3):814-21. PubMed ID: 24574754 [TBL] [Abstract][Full Text] [Related]
40. Blood-based biomarkers used to predict disease activity in Crohn's disease and ulcerative colitis. Burakoff R; Pabby V; Onyewadume L; Odze R; Adackapara C; Wang W; Friedman S; Hamilton M; Korzenik J; Levine J; Makrauer F; Cheng C; Smith HC; Liew CC; Chao S Inflamm Bowel Dis; 2015 May; 21(5):1132-40. PubMed ID: 25895006 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]